Edwards Lifesciences, focused on technologies that treat structural heart disease and critically ill patients, is trading in a bullish trend and several arguments are in favor of the continuation of this trend.

The economic and financial situation of the company is still strong. Estimated sales from Thomson Reuters consensus are encouraging at USD 2.7 billion for 2016. Margins are also interesting more than 20% expected for 2016.

From a technical viewpoint, the security is trading in a bullish trend in the short and the long term. Increasing moving averages let think there will be no reversal in the coming trading sessions. This growth should help to reach soon the USD 91.8 long term resistance.

Therefore, taking into account the strong fundamentals and technical patterns, it seems opportune to open a long trade at current prices in order to benefit from a possible reversal. The main target price is the USD 91.9 long term resistance. A breakout of this level will be a new bullish signal for higher target prices. A stop-loss will be placed under the USD 86, threshold that would invalidate this trading strategy.